Traws Pharma, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate
Traws Pharma, Inc. (TRAW) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate of 3.76% for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate · last filed 2026-08-14
- Traws Pharma, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2026-03-31 was 3.76%, a 14.93% decline year-over-year.
- Traws Pharma, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2025-03-31 was 4.42%.
- Traws Pharma, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2023-03-31 was 3.63%, a 101.67% increase year-over-year.
- Traws Pharma, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2022-03-31 was 1.80%.
- Traws Pharma, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2025 was 3.82%, a 10.40% increase from fiscal 2024.
- Traws Pharma, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2024 was 3.46%, a 13.50% decline from fiscal 2023.
- Traws Pharma, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2023 was 4.00%, a 48.15% increase from fiscal 2022.
- Traws Pharma, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2022 was 2.70%, a 203.37% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | 3.76% 10-Q · filed 2026-08-14 | ||||
| 2026-03-31 | 3.76% 10-Q · filed 2026-05-15 | ||||
| 2025-12-31 | 3.82% 10-K · filed 2026-04-15 | ||||
| 2025-09-30 | 4.17% 10-Q · filed 2025-11-13 | ||||
| 2025-06-30 | 4.17% 10-Q · filed 2026-08-14 | ||||
| 2025-03-31 | 4.42% 10-Q · filed 2026-05-15 | ||||
| 2024-12-31 | 3.46% 10-K · filed 2026-04-15 | ||||
| 2024-09-30 | 3.46% 10-Q · filed 2025-11-13 | ||||
| 2023-12-31 | 4.00% 10-K · filed 2025-03-31 | ||||
| 2023-09-30 | 3.89% 10-Q · filed 2024-11-14 | ||||
| 2023-06-30 | 3.63% 10-Q · filed 2024-08-15 | ||||
| 2023-03-31 | 3.63% 10-Q · filed 2024-05-15 | ||||
| 2022-12-31 | 2.70% 10-K · filed 2024-04-01 | 2.65% 10-K · filed 2023-03-30 | |||
| 2022-09-30 | 2.45% 10-Q · filed 2023-11-14 | ||||
| 2022-06-30 | 2.01% 10-Q · filed 2023-08-14 | ||||
| 2022-03-31 | 1.80% 10-Q · filed 2023-05-15 | ||||
| 2021-12-31 | 0.89% 10-K · filed 2023-03-30 | ||||
| 2020-12-31 | 0.45% 10-K · filed 2021-03-18 | ||||
| 2019-12-31 | 1.77% 10-K · filed 2021-03-18 | ||||
| 2018-12-31 | 2.84% 10-K · filed 2020-03-27 | ||||
| 2017-12-31 | 2.09% 10-K · filed 2019-04-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B |